Sonen Capital LLC Has $1.04 Million Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

Sonen Capital LLC grew its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 9.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,963 shares of the medical research company’s stock after buying an additional 162 shares during the period. Thermo Fisher Scientific accounts for 2.0% of Sonen Capital LLC’s investment portfolio, making the stock its 8th largest position. Sonen Capital LLC’s holdings in Thermo Fisher Scientific were worth $1,042,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in TMO. Sugarloaf Wealth Management LLC boosted its holdings in Thermo Fisher Scientific by 6.9% in the 4th quarter. Sugarloaf Wealth Management LLC now owns 294 shares of the medical research company’s stock worth $156,000 after buying an additional 19 shares during the period. Rosenberg Matthew Hamilton raised its stake in Thermo Fisher Scientific by 3.7% during the fourth quarter. Rosenberg Matthew Hamilton now owns 526 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 19 shares in the last quarter. Tsfg LLC increased its holdings in shares of Thermo Fisher Scientific by 8.3% in the 4th quarter. Tsfg LLC now owns 249 shares of the medical research company’s stock worth $132,000 after buying an additional 19 shares during the last quarter. Pacifica Partners Inc. lifted its holdings in shares of Thermo Fisher Scientific by 16.5% in the 4th quarter. Pacifica Partners Inc. now owns 141 shares of the medical research company’s stock valued at $69,000 after acquiring an additional 20 shares during the last quarter. Finally, Retirement Planning Group LLC increased its stake in Thermo Fisher Scientific by 4.9% during the fourth quarter. Retirement Planning Group LLC now owns 446 shares of the medical research company’s stock worth $237,000 after acquiring an additional 21 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares in the company, valued at $27,311,992.65. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, SVP Michael A. Boxer sold 14,566 shares of the stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total value of $8,186,092.00. Following the completion of the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $555.63, for a total value of $5,556,300.00. Following the sale, the chief executive officer now directly owns 49,155 shares of the company’s stock, valued at $27,311,992.65. The disclosure for this sale can be found here. In the last three months, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.32% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $573.60 on Friday. The company has a quick ratio of 1.39, a current ratio of 1.70 and a debt-to-equity ratio of 0.68. Thermo Fisher Scientific Inc. has a 52 week low of $415.60 and a 52 week high of $603.82. The business’s 50 day moving average price is $573.60 and its 200 day moving average price is $530.14. The firm has a market cap of $218.95 billion, a P/E ratio of 36.79, a P/E/G ratio of 2.42 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. The firm had revenue of $10.35 billion for the quarter, compared to analyst estimates of $10.14 billion. Thermo Fisher Scientific had a return on equity of 18.45% and a net margin of 14.20%. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Monday, April 15th. Stockholders of record on Friday, March 15th were paid a dividend of $0.39 per share. The ex-dividend date was Thursday, March 14th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is currently 10.01%.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on TMO shares. The Goldman Sachs Group increased their price target on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. JPMorgan Chase & Co. raised their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research note on Thursday. Barclays raised their price target on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research note on Thursday. HSBC boosted their target price on shares of Thermo Fisher Scientific from $630.00 to $660.00 and gave the company a “buy” rating in a research note on Wednesday, April 17th. Finally, Citigroup began coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. Five investment analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $606.76.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.